Latest news about Parmax Pharma
Parmax Pharma
59.32
+2.82(+4.99%)
Company Performance:
View Company Insights1D+4.99%
1M+81.19%
6M+99.93%
1Y+52.26%
5Y-17.50%
More news about Parmax Pharma
17Apr 26
Parmax Pharma Limited Files SEBI Compliance Certificate for Q4 FY26 Dematerialization Process
Parmax Pharma Limited filed its Q4 FY26 compliance certificate under SEBI Regulation 74(5) on April 17, 2026, confirming proper dematerialization procedures during the quarter ended March 31, 2026. The company dematerialized 200 shares for shareholder Ketan R Jani through two certificates processed on January 23, 2026. Registrar Purva Sharegistry (India) Pvt. Ltd. provided confirmation of compliance with prescribed timelines and verification procedures.
25Mar 26
Parmax Pharma Limited Appoints Ms. Bhakti Aghera as Company Secretary and Compliance Officer
Parmax Pharma Limited has appointed Ms. Bhakti Aghera as Company Secretary and Compliance Officer effective March 25, 2026. The Board of Directors approved the appointment based on the Nomination and Remuneration Committee's recommendation. Ms. Aghera is an ICSI associate member with six years of corporate legal and secretarial experience and has previously worked with the company.
15Feb 26
Parmax Pharma Reports Q3 FY26 Net Loss of Rs 73.19 Lakh, Revenue Drops 31.2% YoY
Parmax Pharma Limited announced deteriorating Q3 FY26 results with net loss widening to Rs 73.19 lakh from Rs 39.45 lakh year-on-year, while revenue dropped 31.2% to Rs 432.57 lakh. Nine-month performance showed even steeper declines with 62.4% revenue drop and losses mounting to Rs 357.48 lakh. The Board of Directors approved these unaudited results on February 14, 2026, ensuring regulatory compliance under SEBI regulations.
17Nov 25
Parmax Pharma Reports Significant Loss of Rs 284.29 Crore for H1 2025
Parmax Pharma Limited reported significant financial losses for the half-year ended September 30, 2025. Despite a 21.25% increase in revenue to Rs 447.32 crore, the company's net loss widened by 40.69% to Rs 284.29 crore. Total expenses surged by 28.01% to Rs 732.97 crore, outpacing revenue growth. The basic EPS declined to -Rs 7.60 from -Rs 5.40 in the previous year. Auditors noted pending insurance claims and non-provision of depreciation on certain assets.
05Sept 25
Parmax Pharma Reports Mixed Financial Results for FY 2023 with Revenue Decline
Parmax Pharma Limited's FY 2023 results show a decline in performance. Annual revenue decreased to Rs 154,243.45 thousand from Rs 182,511.20 thousand in FY 2022. The company reported a net loss of Rs 1,040.68 thousand, compared to a profit of Rs 1,415.13 thousand in the previous year. Quarterly revenue for Q4 2023 was Rs 63,819.33 thousand, down from Rs 70,879.78 thousand in Q4 2022. However, the company posted a quarterly net profit of Rs 1,729.60 thousand. Total assets stood at Rs 176,126.31 thousand as of March 31, 2023. The statutory auditors issued an unmodified opinion on the financial results.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Cipla
Zydus Life Science
Dr Reddys Laboratories
Lupin
Mankind Pharma
Aurobindo Pharma
Laurus Labs
1,807.70
(+0.75%)
6,638.00
(-0.26%)
4,571.20
(-0.02%)
1,389.40
(+0.44%)
1,104.70
(-0.11%)
1,275.40
(-0.05%)
2,293.30
(+0.88%)
2,381.10
(+0.35%)
1,472.80
(+0.59%)
1,394.30
(+0.25%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
